Review



147sm anti cd20  (fluidigm)


Bioz Verified Symbol fluidigm is a verified supplier
Bioz Manufacturer Symbol fluidigm manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    fluidigm 147sm anti cd20
    147sm Anti Cd20, supplied by fluidigm, used in various techniques. Bioz Stars score: 94/100, based on 9 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/3147001b/Anti-Human+CD20+(2H7)-147Sm/pmc12866138-13-0-5
    Average 94 stars, based on 9 article reviews
    147sm anti cd20 - by Bioz Stars, 2026-10
    94/100 stars

    Images

    Related Articles

    Recombinase Polymerase Amplification:

    Article Title: Multiomics approaches disclose very-early molecular and cellular switches during insect-venom allergen-specific immunotherapy: an observational study
    Article Snippet: .. The list of CyTOF Abs used in this work: Metal Isotope, Antibody, Ab Amount (μl), Clone, Manufacturer, Catalogue#, LOT# (whenever available; if more than one LOT was used, they are split by '&') 154Sm CD3, 1, UCHT1, Fluidigm, 3154003B, 0151806 174Yb CD4, 1, SK3, Fluidigm, 3174004B, 2351715 146Nd CD8a, 1, RPA-T8, Fluidigm, 3146001B,1671716 209Bi CD11b, 1, ICRF44, Fluidigm, 3209003B, 0831723 160Gd CD14, 1, M5E2, Fluidigm, 3160001B, 3261702 164Dy CD15 (SSEA-1), 1, W6D3, Fluidigm, 3164001B, 1421725 148Nd CD16, 1, 3G8, Fluidigm, 3148004B, 2511709 142Nd CD19, 1, HIB19, Fluidigm, 3142001B, 0171815 147Sm CD20, 1, 2H7, Fluidigm, 3147001B, 2491705 166Er CD24, 1, ML5, Fluidigm, 3166007B, 2651709 149Sm CD25 (IL-2R), 1, 2A3, Fluidigm, 3149010B, 1931712 6 nature portfolio | rep orting sum m ary April2023 167Er CD27, 1, L128, Fluidigm, 3167006B, 3501404 172Yb CD38, 1, HIT2, Fluidigm, 3172007B, 1931716 171Yb CD44, 0.1, IM7, Fluidigm, 3171003B, 1931725 & 3421608 89Y CD45, 1, HI30, Fluidigm, 3089003B, 3421702 165Ho CD45RO, 1, UCHL1, Fluidigm, 3165011B, 1421721 153Eu CD45RA, 1, HI100, Fluidigm, 3153001B, 0641506 & 641506 155Gd CD56 (NCAM), 1, B159, Fluidigm, 3155008B, 2771704 & 1471501 150Nd CD63, 1, H5C6, Fluidigm, 3150021B, 1801513 152Sm CD66b, 1, 80H3, Fluidigm, 3152011B, 3491401 144Nd CD69, 1, FN50, Fluidigm, 3144018B, 3041705 143Nd CD117 (cKit), 1, 104D2, Fluidigm, 3143001B, 1711722 151Eu CD123 (IL-3R), 1, 6H6, Fluidigm, 3151001B, 2291711 168Er CD127 (IL-7a), 1, A019D5, Fluidigm, 3168017B, 0541706 145Nd CD138, 1, DL-101, Fluidigm, 3145003B, 2651706 159Tb CD161, 1, HP-3G10, Fluidigm, 3159004B, 1361705 156Gd CD183 (CXCR3), 1, G025H7, Fluidigm, 3156004B, 2771708 175Lu CD194 (CCR4)#, 1, 205410, Fluidigm, 3175021A, 2791705 141Pr CD196 (CCR6), 1, 11A9, Fluidigm, 3141014A, 0751705 163Dy CD294 (CRTH2), 1, BM16, Fluidigm, 3163003B, 1671717 & 691605 170Er HLA-DR, 1, L243, Fluidigm, 3170013B, 3571502 161Dy CD152 (CTLA4), 1, 14D3, Fluidigm, 3161004B, 2651711 169Tm CD30*, 1, 81337, R&D, MAB229, Not available 158Gd CD11c*, 1, 3.9, Biolegend, 301639, Not available 173Yb FceR1/ FCER1A*, 1, AER-37 (CRA1), Thermo Fisher Scientific, 16-5899-82, Not available 176Yb TCR*, 1, B1.1, Thermo Fisher Scientific, 16-9959-81, Not available Notes, * in-house conjugation using Maxpar X8 Antibody Labeling Kits. .. The list of CyTOF Abs used in this work: Metal Isotope, Antibody, Ab Amount (μl), Clone, Manufacturer, Catalogue#, LOT# (whenever available; if more than one LOT was used, they are split by '&') 154Sm CD3, 1, UCHT1, Fluidigm, 3154003B, 0151806 174Yb CD4, 1, SK3, Fluidigm, 3174004B, 2351715 146Nd CD8a, 1, RPA-T8, Fluidigm, 3146001B,1671716 209Bi CD11b, 1, ICRF44, Fluidigm, 3209003B, 0831723 160Gd CD14, 1, M5E2, Fluidigm, 3160001B, 3261702 164Dy CD15 (SSEA-1), 1, W6D3, Fluidigm, 3164001B, 1421725 148Nd CD16, 1, 3G8, Fluidigm, 3148004B, 2511709 142Nd CD19, 1, HIB19, Fluidigm, 3142001B, 0171815 147Sm CD20, 1, 2H7, Fluidigm, 3147001B, 2491705 166Er CD24, 1, ML5, Fluidigm, 3166007B, 2651709 149Sm CD25 (IL-2R), 1, 2A3, Fluidigm, 3149010B, 1931712 6 nature portfolio | rep orting sum m ary April2023 167Er CD27, 1, L128, Fluidigm, 3167006B, 3501404 172Yb CD38, 1, HIT2, Fluidigm, 3172007B, 1931716 171Yb CD44, 0.1, IM7, Fluidigm, 3171003B, 1931725 & 3421608 89Y CD45, 1, HI30, Fluidigm, 3089003B, 3421702 165Ho CD45RO, 1, UCHL1, Fluidigm, 3165011B, 1421721 153Eu CD45RA, 1, HI100, Fluidigm, 3153001B, 0641506 & 641506 155Gd CD56 (NCAM), 1, B159, Fluidigm, 3155008B, 2771704 & 1471501 150Nd CD63, 1, H5C6, Fluidigm, 3150021B, 1801513 152Sm CD66b, 1, 80H3, Fluidigm, 3152011B, 3491401 144Nd CD69, 1, FN50, Fluidigm, 3144018B, 3041705 143Nd CD117 (cKit), 1, 104D2, Fluidigm, 3143001B, 1711722 151Eu CD123 (IL-3R), 1, 6H6, Fluidigm, 3151001B, 2291711 168Er CD127 (IL-7a), 1, A019D5, Fluidigm, 3168017B, 0541706 145Nd CD138, 1, DL-101, Fluidigm, 3145003B, 2651706 159Tb CD161, 1, HP-3G10, Fluidigm, 3159004B, 1361705 156Gd CD183 (CXCR3), 1, G025H7, Fluidigm, 3156004B, 2771708 175Lu CD194 (CCR4)#, 1, 205410, Fluidigm, 3175021A, 2791705 141Pr CD196 (CCR6), 1, 11A9, Fluidigm, 3141014A, 0751705 163Dy CD294 (CRTH2), 1, BM16, Fluidigm, 3163003B, 1671717 & 691605 170Er HLA-DR, 1, L243, Fluidigm, 3170013B, 3571502 161Dy CD152 (CTLA4), 1, 14D3, Fluidigm, 3161004B, 2651711 169Tm CD30*, 1, 81337, R&D, MAB229, Not available 158Gd CD11c*, 1, 3.9, Biolegend, 301639, Not available 173Yb FceR1/ FCER1A*, 1, AER-37 (CRA1), Thermo Fisher Scientific, 16-5899-82, Not available 176Yb TCR*, 1, B1.1, Thermo Fisher Scientific, 16-9959-81, Not available Notes, * in-house conjugation using Maxpar X8 Antibody Labeling Kits.

    Article Title: BCG vaccination induces antibacterial effector functions among Vδ1/3 T cells that are associated with protection against tuberculosis.
    Article Snippet: .. REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies 116Cd anti-CD45 (clone D058-1283) BD Biosciences Cat #552566 106Cd anti-CD68 (clone KP1) BioLegend Cat #916104 172Yb anti-CD206 (clone 19.2) BD Biosciences Cat #555953 154Sm anti-CD163 (clone GHI/61) Fluidigm Cat #3154007B 151Eu anti-CD14 (clone M5E2) Fluidigm Cat #3151009B 144ND anti-CD11b (Mac-1) (clone ICRF44) Fluidigm Cat #3144001B 209Bi anti-CD16 (clone 3G8) Fluidigm Cat #3209002B 146ND anti-CD11c (clone 3.9) Fluidigm Cat #3146014B 161Dy anti-CD123 (clone 6H6) BioLegend Cat #306002 176Yb anti-HLA-DR (clone LN3) BioLegend Cat #327002 169Tm anti-NKG2A (clone Z199) Fluidigm Cat #3169013B 147Sm anti-CD20 (clone 2H7) Fluidigm Cat #3147001B 153Eu anti-IgD (Polyclonal) Southern Biotech Cat #2030-01 170Er anti-CD3 (clone SP34-2) Fluidigm Cat #3170007B APC anti-MR1-5-OP-RU Tetramer NIH Tetramer Core N/A 163Dy anti- anti-APC Fluidigm Cat #3163001B 171Yb anti-TCRγδ (clone B1) BioLegend Cat #331202 112Cd anti-TCR Vγ9 (clone B3) BioLegend Cat #331301 160Gd anti-CD161 (clone HP-3G10) BioLegend Cat #339902 111Cd anti-CD8α (clone RPA-T8) BioLegend Cat #301053 113Cd anti-CD8β (clone 2ST8.5H7) Novus Biologicals Cat #NB100-65928 114Cd anti-CD4 (clone L200) BD Biosciences Cat #550625 174Yb anti-CD45RA (clone 5H9) BD Biosciences Cat #556625 175Lu anti-CD28 (clone CD28.2) BioLegend Cat #302902 159Tb anti-CCR7 (clone G043H7) Fluidigm Cat #3159003A 156Gd anti-CXCR3 (clone G025H7) Fluidigm Cat #3156004B 145ND anti-CD69 (clone FN50) BioLegend Cat #310902 173Yb anti-Granzyme B (clone GB11) Fluidigm Cat #3173006B 165Ho anti-Granzyme K (clone GM26E7) BioLegend Cat #370502 164Dy anti-Perforin (clone Pf-80/164) Mabtech Cat #3465-3-250 143ND anti-CD107a (clone H4A3) BioLegend Cat #328601 162Dy anti-CD154 (clone 24–31) BioLegend Cat #310802 152Sm anti-TNF (clone Mab11) Fluidigm Cat #3152002B 168Er anti-IFN-g (clone B27) Fluidigm Cat #3168005B 158Gd anti-IL-2 (clone MQ1-17H12) Fluidigm Cat #3158007B 148ND anti-IL-17A (clone BL168) Fluidigm Cat #3148008B Cell-ID Intercalator Ir Fluidigm Cat #201192A Cell-ID Cisplatin Fluidigm Cat # 201064 FITC anti-TNF (clone Mab11) BD Biosciences Cat #554512 BB700 anti-CD8 (clone RPA-T8) BD Biosciences Cat #566452 PE anti-Granzyme K (clone GM26E7) BioLegend Cat #370512 PE-CF594 anti-Granzyme B (clone GB11) BD Biosciences Cat #562462 (Continued on next page) Cell Reports Medicine 7, 102536, January 20, 2026 e1 OPEN ACCESS ..

    Conjugation Assay:

    Article Title: Multiomics approaches disclose very-early molecular and cellular switches during insect-venom allergen-specific immunotherapy: an observational study
    Article Snippet: .. The list of CyTOF Abs used in this work: Metal Isotope, Antibody, Ab Amount (μl), Clone, Manufacturer, Catalogue#, LOT# (whenever available; if more than one LOT was used, they are split by '&') 154Sm CD3, 1, UCHT1, Fluidigm, 3154003B, 0151806 174Yb CD4, 1, SK3, Fluidigm, 3174004B, 2351715 146Nd CD8a, 1, RPA-T8, Fluidigm, 3146001B,1671716 209Bi CD11b, 1, ICRF44, Fluidigm, 3209003B, 0831723 160Gd CD14, 1, M5E2, Fluidigm, 3160001B, 3261702 164Dy CD15 (SSEA-1), 1, W6D3, Fluidigm, 3164001B, 1421725 148Nd CD16, 1, 3G8, Fluidigm, 3148004B, 2511709 142Nd CD19, 1, HIB19, Fluidigm, 3142001B, 0171815 147Sm CD20, 1, 2H7, Fluidigm, 3147001B, 2491705 166Er CD24, 1, ML5, Fluidigm, 3166007B, 2651709 149Sm CD25 (IL-2R), 1, 2A3, Fluidigm, 3149010B, 1931712 6 nature portfolio | rep orting sum m ary April2023 167Er CD27, 1, L128, Fluidigm, 3167006B, 3501404 172Yb CD38, 1, HIT2, Fluidigm, 3172007B, 1931716 171Yb CD44, 0.1, IM7, Fluidigm, 3171003B, 1931725 & 3421608 89Y CD45, 1, HI30, Fluidigm, 3089003B, 3421702 165Ho CD45RO, 1, UCHL1, Fluidigm, 3165011B, 1421721 153Eu CD45RA, 1, HI100, Fluidigm, 3153001B, 0641506 & 641506 155Gd CD56 (NCAM), 1, B159, Fluidigm, 3155008B, 2771704 & 1471501 150Nd CD63, 1, H5C6, Fluidigm, 3150021B, 1801513 152Sm CD66b, 1, 80H3, Fluidigm, 3152011B, 3491401 144Nd CD69, 1, FN50, Fluidigm, 3144018B, 3041705 143Nd CD117 (cKit), 1, 104D2, Fluidigm, 3143001B, 1711722 151Eu CD123 (IL-3R), 1, 6H6, Fluidigm, 3151001B, 2291711 168Er CD127 (IL-7a), 1, A019D5, Fluidigm, 3168017B, 0541706 145Nd CD138, 1, DL-101, Fluidigm, 3145003B, 2651706 159Tb CD161, 1, HP-3G10, Fluidigm, 3159004B, 1361705 156Gd CD183 (CXCR3), 1, G025H7, Fluidigm, 3156004B, 2771708 175Lu CD194 (CCR4)#, 1, 205410, Fluidigm, 3175021A, 2791705 141Pr CD196 (CCR6), 1, 11A9, Fluidigm, 3141014A, 0751705 163Dy CD294 (CRTH2), 1, BM16, Fluidigm, 3163003B, 1671717 & 691605 170Er HLA-DR, 1, L243, Fluidigm, 3170013B, 3571502 161Dy CD152 (CTLA4), 1, 14D3, Fluidigm, 3161004B, 2651711 169Tm CD30*, 1, 81337, R&D, MAB229, Not available 158Gd CD11c*, 1, 3.9, Biolegend, 301639, Not available 173Yb FceR1/ FCER1A*, 1, AER-37 (CRA1), Thermo Fisher Scientific, 16-5899-82, Not available 176Yb TCR*, 1, B1.1, Thermo Fisher Scientific, 16-9959-81, Not available Notes, * in-house conjugation using Maxpar X8 Antibody Labeling Kits. .. The list of CyTOF Abs used in this work: Metal Isotope, Antibody, Ab Amount (μl), Clone, Manufacturer, Catalogue#, LOT# (whenever available; if more than one LOT was used, they are split by '&') 154Sm CD3, 1, UCHT1, Fluidigm, 3154003B, 0151806 174Yb CD4, 1, SK3, Fluidigm, 3174004B, 2351715 146Nd CD8a, 1, RPA-T8, Fluidigm, 3146001B,1671716 209Bi CD11b, 1, ICRF44, Fluidigm, 3209003B, 0831723 160Gd CD14, 1, M5E2, Fluidigm, 3160001B, 3261702 164Dy CD15 (SSEA-1), 1, W6D3, Fluidigm, 3164001B, 1421725 148Nd CD16, 1, 3G8, Fluidigm, 3148004B, 2511709 142Nd CD19, 1, HIB19, Fluidigm, 3142001B, 0171815 147Sm CD20, 1, 2H7, Fluidigm, 3147001B, 2491705 166Er CD24, 1, ML5, Fluidigm, 3166007B, 2651709 149Sm CD25 (IL-2R), 1, 2A3, Fluidigm, 3149010B, 1931712 6 nature portfolio | rep orting sum m ary April2023 167Er CD27, 1, L128, Fluidigm, 3167006B, 3501404 172Yb CD38, 1, HIT2, Fluidigm, 3172007B, 1931716 171Yb CD44, 0.1, IM7, Fluidigm, 3171003B, 1931725 & 3421608 89Y CD45, 1, HI30, Fluidigm, 3089003B, 3421702 165Ho CD45RO, 1, UCHL1, Fluidigm, 3165011B, 1421721 153Eu CD45RA, 1, HI100, Fluidigm, 3153001B, 0641506 & 641506 155Gd CD56 (NCAM), 1, B159, Fluidigm, 3155008B, 2771704 & 1471501 150Nd CD63, 1, H5C6, Fluidigm, 3150021B, 1801513 152Sm CD66b, 1, 80H3, Fluidigm, 3152011B, 3491401 144Nd CD69, 1, FN50, Fluidigm, 3144018B, 3041705 143Nd CD117 (cKit), 1, 104D2, Fluidigm, 3143001B, 1711722 151Eu CD123 (IL-3R), 1, 6H6, Fluidigm, 3151001B, 2291711 168Er CD127 (IL-7a), 1, A019D5, Fluidigm, 3168017B, 0541706 145Nd CD138, 1, DL-101, Fluidigm, 3145003B, 2651706 159Tb CD161, 1, HP-3G10, Fluidigm, 3159004B, 1361705 156Gd CD183 (CXCR3), 1, G025H7, Fluidigm, 3156004B, 2771708 175Lu CD194 (CCR4)#, 1, 205410, Fluidigm, 3175021A, 2791705 141Pr CD196 (CCR6), 1, 11A9, Fluidigm, 3141014A, 0751705 163Dy CD294 (CRTH2), 1, BM16, Fluidigm, 3163003B, 1671717 & 691605 170Er HLA-DR, 1, L243, Fluidigm, 3170013B, 3571502 161Dy CD152 (CTLA4), 1, 14D3, Fluidigm, 3161004B, 2651711 169Tm CD30*, 1, 81337, R&D, MAB229, Not available 158Gd CD11c*, 1, 3.9, Biolegend, 301639, Not available 173Yb FceR1/ FCER1A*, 1, AER-37 (CRA1), Thermo Fisher Scientific, 16-5899-82, Not available 176Yb TCR*, 1, B1.1, Thermo Fisher Scientific, 16-9959-81, Not available Notes, * in-house conjugation using Maxpar X8 Antibody Labeling Kits.

    Antibody Labeling:

    Article Title: Multiomics approaches disclose very-early molecular and cellular switches during insect-venom allergen-specific immunotherapy: an observational study
    Article Snippet: .. The list of CyTOF Abs used in this work: Metal Isotope, Antibody, Ab Amount (μl), Clone, Manufacturer, Catalogue#, LOT# (whenever available; if more than one LOT was used, they are split by '&') 154Sm CD3, 1, UCHT1, Fluidigm, 3154003B, 0151806 174Yb CD4, 1, SK3, Fluidigm, 3174004B, 2351715 146Nd CD8a, 1, RPA-T8, Fluidigm, 3146001B,1671716 209Bi CD11b, 1, ICRF44, Fluidigm, 3209003B, 0831723 160Gd CD14, 1, M5E2, Fluidigm, 3160001B, 3261702 164Dy CD15 (SSEA-1), 1, W6D3, Fluidigm, 3164001B, 1421725 148Nd CD16, 1, 3G8, Fluidigm, 3148004B, 2511709 142Nd CD19, 1, HIB19, Fluidigm, 3142001B, 0171815 147Sm CD20, 1, 2H7, Fluidigm, 3147001B, 2491705 166Er CD24, 1, ML5, Fluidigm, 3166007B, 2651709 149Sm CD25 (IL-2R), 1, 2A3, Fluidigm, 3149010B, 1931712 6 nature portfolio | rep orting sum m ary April2023 167Er CD27, 1, L128, Fluidigm, 3167006B, 3501404 172Yb CD38, 1, HIT2, Fluidigm, 3172007B, 1931716 171Yb CD44, 0.1, IM7, Fluidigm, 3171003B, 1931725 & 3421608 89Y CD45, 1, HI30, Fluidigm, 3089003B, 3421702 165Ho CD45RO, 1, UCHL1, Fluidigm, 3165011B, 1421721 153Eu CD45RA, 1, HI100, Fluidigm, 3153001B, 0641506 & 641506 155Gd CD56 (NCAM), 1, B159, Fluidigm, 3155008B, 2771704 & 1471501 150Nd CD63, 1, H5C6, Fluidigm, 3150021B, 1801513 152Sm CD66b, 1, 80H3, Fluidigm, 3152011B, 3491401 144Nd CD69, 1, FN50, Fluidigm, 3144018B, 3041705 143Nd CD117 (cKit), 1, 104D2, Fluidigm, 3143001B, 1711722 151Eu CD123 (IL-3R), 1, 6H6, Fluidigm, 3151001B, 2291711 168Er CD127 (IL-7a), 1, A019D5, Fluidigm, 3168017B, 0541706 145Nd CD138, 1, DL-101, Fluidigm, 3145003B, 2651706 159Tb CD161, 1, HP-3G10, Fluidigm, 3159004B, 1361705 156Gd CD183 (CXCR3), 1, G025H7, Fluidigm, 3156004B, 2771708 175Lu CD194 (CCR4)#, 1, 205410, Fluidigm, 3175021A, 2791705 141Pr CD196 (CCR6), 1, 11A9, Fluidigm, 3141014A, 0751705 163Dy CD294 (CRTH2), 1, BM16, Fluidigm, 3163003B, 1671717 & 691605 170Er HLA-DR, 1, L243, Fluidigm, 3170013B, 3571502 161Dy CD152 (CTLA4), 1, 14D3, Fluidigm, 3161004B, 2651711 169Tm CD30*, 1, 81337, R&D, MAB229, Not available 158Gd CD11c*, 1, 3.9, Biolegend, 301639, Not available 173Yb FceR1/ FCER1A*, 1, AER-37 (CRA1), Thermo Fisher Scientific, 16-5899-82, Not available 176Yb TCR*, 1, B1.1, Thermo Fisher Scientific, 16-9959-81, Not available Notes, * in-house conjugation using Maxpar X8 Antibody Labeling Kits. .. The list of CyTOF Abs used in this work: Metal Isotope, Antibody, Ab Amount (μl), Clone, Manufacturer, Catalogue#, LOT# (whenever available; if more than one LOT was used, they are split by '&') 154Sm CD3, 1, UCHT1, Fluidigm, 3154003B, 0151806 174Yb CD4, 1, SK3, Fluidigm, 3174004B, 2351715 146Nd CD8a, 1, RPA-T8, Fluidigm, 3146001B,1671716 209Bi CD11b, 1, ICRF44, Fluidigm, 3209003B, 0831723 160Gd CD14, 1, M5E2, Fluidigm, 3160001B, 3261702 164Dy CD15 (SSEA-1), 1, W6D3, Fluidigm, 3164001B, 1421725 148Nd CD16, 1, 3G8, Fluidigm, 3148004B, 2511709 142Nd CD19, 1, HIB19, Fluidigm, 3142001B, 0171815 147Sm CD20, 1, 2H7, Fluidigm, 3147001B, 2491705 166Er CD24, 1, ML5, Fluidigm, 3166007B, 2651709 149Sm CD25 (IL-2R), 1, 2A3, Fluidigm, 3149010B, 1931712 6 nature portfolio | rep orting sum m ary April2023 167Er CD27, 1, L128, Fluidigm, 3167006B, 3501404 172Yb CD38, 1, HIT2, Fluidigm, 3172007B, 1931716 171Yb CD44, 0.1, IM7, Fluidigm, 3171003B, 1931725 & 3421608 89Y CD45, 1, HI30, Fluidigm, 3089003B, 3421702 165Ho CD45RO, 1, UCHL1, Fluidigm, 3165011B, 1421721 153Eu CD45RA, 1, HI100, Fluidigm, 3153001B, 0641506 & 641506 155Gd CD56 (NCAM), 1, B159, Fluidigm, 3155008B, 2771704 & 1471501 150Nd CD63, 1, H5C6, Fluidigm, 3150021B, 1801513 152Sm CD66b, 1, 80H3, Fluidigm, 3152011B, 3491401 144Nd CD69, 1, FN50, Fluidigm, 3144018B, 3041705 143Nd CD117 (cKit), 1, 104D2, Fluidigm, 3143001B, 1711722 151Eu CD123 (IL-3R), 1, 6H6, Fluidigm, 3151001B, 2291711 168Er CD127 (IL-7a), 1, A019D5, Fluidigm, 3168017B, 0541706 145Nd CD138, 1, DL-101, Fluidigm, 3145003B, 2651706 159Tb CD161, 1, HP-3G10, Fluidigm, 3159004B, 1361705 156Gd CD183 (CXCR3), 1, G025H7, Fluidigm, 3156004B, 2771708 175Lu CD194 (CCR4)#, 1, 205410, Fluidigm, 3175021A, 2791705 141Pr CD196 (CCR6), 1, 11A9, Fluidigm, 3141014A, 0751705 163Dy CD294 (CRTH2), 1, BM16, Fluidigm, 3163003B, 1671717 & 691605 170Er HLA-DR, 1, L243, Fluidigm, 3170013B, 3571502 161Dy CD152 (CTLA4), 1, 14D3, Fluidigm, 3161004B, 2651711 169Tm CD30*, 1, 81337, R&D, MAB229, Not available 158Gd CD11c*, 1, 3.9, Biolegend, 301639, Not available 173Yb FceR1/ FCER1A*, 1, AER-37 (CRA1), Thermo Fisher Scientific, 16-5899-82, Not available 176Yb TCR*, 1, B1.1, Thermo Fisher Scientific, 16-9959-81, Not available Notes, * in-house conjugation using Maxpar X8 Antibody Labeling Kits.

    other:




    Similar Products

    94
    fluidigm 147sm anti cd20
    147sm Anti Cd20, supplied by fluidigm, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/3147001b/Anti-Human+CD20+(2H7)-147Sm/pmc12866138-13-0-5
    Average 94 stars, based on 1 article reviews
    147sm anti cd20 - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    fluidigm 3147001b
    3147001b, supplied by fluidigm, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/3147001b/Anti-Human+CD20+(2H7)-147Sm/pmc12866138-13-8-5
    Average 94 stars, based on 1 article reviews
    3147001b - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    fluidigm 2h7
    2h7, supplied by fluidigm, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/3147001b/Anti-Human+CD20+(2H7)-147Sm/pmc12318895-6-4-6
    Average 94 stars, based on 1 article reviews
    2h7 - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    fluidigm cd20 147sm 2h7 standard biotools 3147001b 0 7
    FIGURE 1 | TFH cells constitute a phenotypically heterogeneous cell compartment. (A) Tonsillar single cell suspensions (n = 4) were analysed using a CyTOF (N = 34 parameters) assay. The gating scheme for the identification of main cell subsets is shown. (B) Heatmap showing the relative mean expression of selected protein markers in bulk CD4hi memory, CD4hiCXCR5loPD1lo memory and TFH cell subsets (n = 8) in different tonsils (D1- D4). A colour indicator is provided. (C) UMAP analysis demonstrating the clustering of TFH clusters across four individual donors based on selected protein markers. (D) UMAP analysis showing the original clusters and annotations of CD4 tonsillar cells based on scRNA analysis (upper, left panel). The prevalence of PD1hi cells (upper, middle panel) and the subset of <t>CD8−CD20−CD4+PD1+</t> TFH cells (upper, right panel) are shown. Expression of selected marker genes (middle row) and cluster membership per donor (lower row, right) are shown for UMAPs and re-clustering generated using the selected cells from five donors and the genes selected from protein analyses (lower row, left).
    Cd20 147sm 2h7 Standard Biotools 3147001b 0 7, supplied by fluidigm, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/3147001b/Anti-Human+CD20+(2H7)-147Sm/pm40421691-56-50-53
    Average 94 stars, based on 1 article reviews
    cd20 147sm 2h7 standard biotools 3147001b 0 7 - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    Image Search Results


    FIGURE 1 | TFH cells constitute a phenotypically heterogeneous cell compartment. (A) Tonsillar single cell suspensions (n = 4) were analysed using a CyTOF (N = 34 parameters) assay. The gating scheme for the identification of main cell subsets is shown. (B) Heatmap showing the relative mean expression of selected protein markers in bulk CD4hi memory, CD4hiCXCR5loPD1lo memory and TFH cell subsets (n = 8) in different tonsils (D1- D4). A colour indicator is provided. (C) UMAP analysis demonstrating the clustering of TFH clusters across four individual donors based on selected protein markers. (D) UMAP analysis showing the original clusters and annotations of CD4 tonsillar cells based on scRNA analysis (upper, left panel). The prevalence of PD1hi cells (upper, middle panel) and the subset of CD8−CD20−CD4+PD1+ TFH cells (upper, right panel) are shown. Expression of selected marker genes (middle row) and cluster membership per donor (lower row, right) are shown for UMAPs and re-clustering generated using the selected cells from five donors and the genes selected from protein analyses (lower row, left).

    Journal: Immunology

    Article Title: Delineation of the Human Germinal Centre Immune Landscape Using Multiplex Imaging Analysis.

    doi: 10.1111/imm.13955

    Figure Lengend Snippet: FIGURE 1 | TFH cells constitute a phenotypically heterogeneous cell compartment. (A) Tonsillar single cell suspensions (n = 4) were analysed using a CyTOF (N = 34 parameters) assay. The gating scheme for the identification of main cell subsets is shown. (B) Heatmap showing the relative mean expression of selected protein markers in bulk CD4hi memory, CD4hiCXCR5loPD1lo memory and TFH cell subsets (n = 8) in different tonsils (D1- D4). A colour indicator is provided. (C) UMAP analysis demonstrating the clustering of TFH clusters across four individual donors based on selected protein markers. (D) UMAP analysis showing the original clusters and annotations of CD4 tonsillar cells based on scRNA analysis (upper, left panel). The prevalence of PD1hi cells (upper, middle panel) and the subset of CD8−CD20−CD4+PD1+ TFH cells (upper, right panel) are shown. Expression of selected marker genes (middle row) and cluster membership per donor (lower row, right) are shown for UMAPs and re-clustering generated using the selected cells from five donors and the genes selected from protein analyses (lower row, left).

    Article Snippet: Amount Rhodium 103Rh Cell- ID Standard Biotools 201103A 0.6 μL CD8 113ln RPA- T8 BioLegend 301018 0.6 μL CD4 115In RPA- T4 BioLegend 300515 0.6 μL CCR6 141Pr 11A9 Standard Biotools 3141014A 1 μL CD19 142Nd HIB19 Standard Biotools 3142001B 1.6 μL CCR6 144Nd G034E3 Standard Biotools 3141003A 1.88 μL CD20 147Sm 2H7 Standard Biotools 3147001B 0.7 μL ICOS 148Nd C398.4A Standard Biotools 3148019B 1 μL CCR4 149Sm L291H4 Standard Biotools 3149029A 1.5 μL CD40L 152Sm TRAP1 BD Biosciences 555698 3 μL TIGIT 153Eu MBSA43 Standard Biotools 3153019B 2 μL CD3 154Sm UCHT1 Standard Biotools 3154003B 0.5 μL CD27 155Gd L128 Standard Biotools 3155001B 1 μL CXCR3 156Gd G025H7 Standard Biotools 3156004B 0.8 μL CCR7 159 Tb G043H7 Standard Biotools 3159003A 1 μL CD30 162Dy BY88 BioLegend 333902 3 μL CXCR5 164Dy RF8B2 Standard Biotools 3164029B 1.2 μL CD45RO 165Ho UCHL1 Standard Biotools 3165011B 0.7 μL CD38 167Er HIT2 Standard Biotools 3167001B 0.6 μL CD45RA 170Er HI100 Standard Biotools 3171002B 1.6 μL HLA- DR 174Yb L243 Standard Biotools 3174001B 0.7 μL CD279/PD- 1 175Lu EH12.2H7 Standard Biotools 3175008B 1 μL CD127 176Yb A019D5 Standard Biotools 3176004B 0.7 μL CTLA4 194Pt Ipilimumab BMS ACB3065 2.5 μL CD57 198Pt NK- 1 BD Biosciences 555618 1 μL CD16 209Bi 3G8 Standard Biotools 3209002B 1.5 μL TABLE 2 | Antibodies used for the mass cytometry intracellular characterisation of tonsillar- derived cells.

    Techniques: Expressing, Marker, Generated

    FIGURE 2 | In situ phenotypic heterogeneity of TFH cells revealed by mIF imaging. (A) Representative fluorescent images showing the expres- sion of biomarkers CD3 (blue), CD20 (red), CD8 (yellow), CD4 (green), PD1 (cyan) and CD57 (grey) used in the mIF assay. Representative images from one tonsil are shown (scale bar: 150 μm). (B) The histocytometry gating scheme for the identification of B (CD20hi/dim), CD3hi, CD4hi and follic- ular (F) CD3hiPD1hi cells in an LN is shown. Individual follicular areas were identified based on the density of CD20hi/dim cells. All follicular areas were combined (using the FlowJo10 module in one follicle for downstream analysis. The total extrafollicular area is shown. (C) The expression (raw mean fluorescence intensities) of individual biomarkers in F-CD3hiPD1hi TFH, F-CD3hiCD4hiPD1lo non-TFH, extrafollicular (EF)-CD3hiCD8hi and F- CD20hi/dimCD3lo B cells are shown as histograms (upper two rows) or 2D contour plots (biomarker vs. PD1) (lower two rows). Imaging data from an LN were used. (D) Six Histocytometry identified follicular areas (top row) and 2D dot plots showing the associated expression of biomarkers used vs. PD1 in CD3loCD4lo (as reference cell subset-grey) and CD3hiPD1hi TFH cells (purple).

    Journal: Immunology

    Article Title: Delineation of the Human Germinal Centre Immune Landscape Using Multiplex Imaging Analysis.

    doi: 10.1111/imm.13955

    Figure Lengend Snippet: FIGURE 2 | In situ phenotypic heterogeneity of TFH cells revealed by mIF imaging. (A) Representative fluorescent images showing the expres- sion of biomarkers CD3 (blue), CD20 (red), CD8 (yellow), CD4 (green), PD1 (cyan) and CD57 (grey) used in the mIF assay. Representative images from one tonsil are shown (scale bar: 150 μm). (B) The histocytometry gating scheme for the identification of B (CD20hi/dim), CD3hi, CD4hi and follic- ular (F) CD3hiPD1hi cells in an LN is shown. Individual follicular areas were identified based on the density of CD20hi/dim cells. All follicular areas were combined (using the FlowJo10 module in one follicle for downstream analysis. The total extrafollicular area is shown. (C) The expression (raw mean fluorescence intensities) of individual biomarkers in F-CD3hiPD1hi TFH, F-CD3hiCD4hiPD1lo non-TFH, extrafollicular (EF)-CD3hiCD8hi and F- CD20hi/dimCD3lo B cells are shown as histograms (upper two rows) or 2D contour plots (biomarker vs. PD1) (lower two rows). Imaging data from an LN were used. (D) Six Histocytometry identified follicular areas (top row) and 2D dot plots showing the associated expression of biomarkers used vs. PD1 in CD3loCD4lo (as reference cell subset-grey) and CD3hiPD1hi TFH cells (purple).

    Article Snippet: Amount Rhodium 103Rh Cell- ID Standard Biotools 201103A 0.6 μL CD8 113ln RPA- T8 BioLegend 301018 0.6 μL CD4 115In RPA- T4 BioLegend 300515 0.6 μL CCR6 141Pr 11A9 Standard Biotools 3141014A 1 μL CD19 142Nd HIB19 Standard Biotools 3142001B 1.6 μL CCR6 144Nd G034E3 Standard Biotools 3141003A 1.88 μL CD20 147Sm 2H7 Standard Biotools 3147001B 0.7 μL ICOS 148Nd C398.4A Standard Biotools 3148019B 1 μL CCR4 149Sm L291H4 Standard Biotools 3149029A 1.5 μL CD40L 152Sm TRAP1 BD Biosciences 555698 3 μL TIGIT 153Eu MBSA43 Standard Biotools 3153019B 2 μL CD3 154Sm UCHT1 Standard Biotools 3154003B 0.5 μL CD27 155Gd L128 Standard Biotools 3155001B 1 μL CXCR3 156Gd G025H7 Standard Biotools 3156004B 0.8 μL CCR7 159 Tb G043H7 Standard Biotools 3159003A 1 μL CD30 162Dy BY88 BioLegend 333902 3 μL CXCR5 164Dy RF8B2 Standard Biotools 3164029B 1.2 μL CD45RO 165Ho UCHL1 Standard Biotools 3165011B 0.7 μL CD38 167Er HIT2 Standard Biotools 3167001B 0.6 μL CD45RA 170Er HI100 Standard Biotools 3171002B 1.6 μL HLA- DR 174Yb L243 Standard Biotools 3174001B 0.7 μL CD279/PD- 1 175Lu EH12.2H7 Standard Biotools 3175008B 1 μL CD127 176Yb A019D5 Standard Biotools 3176004B 0.7 μL CTLA4 194Pt Ipilimumab BMS ACB3065 2.5 μL CD57 198Pt NK- 1 BD Biosciences 555618 1 μL CD16 209Bi 3G8 Standard Biotools 3209002B 1.5 μL TABLE 2 | Antibodies used for the mass cytometry intracellular characterisation of tonsillar- derived cells.

    Techniques: In Situ, Imaging, Expressing, Fluorescence, Biomarker Discovery

    FIGURE 3 | Differential localisation and distribution profile among TFH cell subsets. (A) Representative fluorescent images showing the expres- sion of CD20 (red), Ki67 (magenta) and Bcl6 (grey) in tonsillar follicles (scale bar: 300 μm). (B) 2D plots showing the expression of Ki67 vs. Bcl6 in total follicular (F) area from one tonsil and the corresponding localisation of F-CD20hi/dimCD3loKi67loBCl6lo (blue-MZ), F-CD20hi/dimCD3loKi67hiBCl6hi (magenta-DZ) and F-CD20hi/dimCD3loKi67loBCl6hi (grey-LZ) (left). The relevant B cell subsets and their localisation for one representative follicle are also shown (right). (C) 2D plots showing the gating for the identification of B subsets (based on the expression of Ki67 and Bcl6) and CD3hiPD1hi TFH cell subsets (based on the expression of CD57, CXCR3, TIGIT and Bcl6) as well as their localisation across the areas of individual follicles (data from one LN). (D) Dot plot graphs showing accumulated data for the analysis of the minimum distance between DZ (CD20hi/dimCD3loKi67hiBcl- 6hi) (open and blue circles) or LZ (CD20hi/dimCD3loKi67loBcl6hi) (green and red circles) B cells and TFH cell subsets (CD3hiPD1hiCD57loCXCR3hi, CD3hiPD1hiCD57hiCXCR3lo) (upper panel) and the corresponding calculated cross-G function (lower panel). Follicular areas from two tonsils and two LNs were analysed, each dot represents a follicle. Statistical analysis was performed using the Wilcoxon and Mann–Whitney tests, and p values are listed.

    Journal: Immunology

    Article Title: Delineation of the Human Germinal Centre Immune Landscape Using Multiplex Imaging Analysis.

    doi: 10.1111/imm.13955

    Figure Lengend Snippet: FIGURE 3 | Differential localisation and distribution profile among TFH cell subsets. (A) Representative fluorescent images showing the expres- sion of CD20 (red), Ki67 (magenta) and Bcl6 (grey) in tonsillar follicles (scale bar: 300 μm). (B) 2D plots showing the expression of Ki67 vs. Bcl6 in total follicular (F) area from one tonsil and the corresponding localisation of F-CD20hi/dimCD3loKi67loBCl6lo (blue-MZ), F-CD20hi/dimCD3loKi67hiBCl6hi (magenta-DZ) and F-CD20hi/dimCD3loKi67loBCl6hi (grey-LZ) (left). The relevant B cell subsets and their localisation for one representative follicle are also shown (right). (C) 2D plots showing the gating for the identification of B subsets (based on the expression of Ki67 and Bcl6) and CD3hiPD1hi TFH cell subsets (based on the expression of CD57, CXCR3, TIGIT and Bcl6) as well as their localisation across the areas of individual follicles (data from one LN). (D) Dot plot graphs showing accumulated data for the analysis of the minimum distance between DZ (CD20hi/dimCD3loKi67hiBcl- 6hi) (open and blue circles) or LZ (CD20hi/dimCD3loKi67loBcl6hi) (green and red circles) B cells and TFH cell subsets (CD3hiPD1hiCD57loCXCR3hi, CD3hiPD1hiCD57hiCXCR3lo) (upper panel) and the corresponding calculated cross-G function (lower panel). Follicular areas from two tonsils and two LNs were analysed, each dot represents a follicle. Statistical analysis was performed using the Wilcoxon and Mann–Whitney tests, and p values are listed.

    Article Snippet: Amount Rhodium 103Rh Cell- ID Standard Biotools 201103A 0.6 μL CD8 113ln RPA- T8 BioLegend 301018 0.6 μL CD4 115In RPA- T4 BioLegend 300515 0.6 μL CCR6 141Pr 11A9 Standard Biotools 3141014A 1 μL CD19 142Nd HIB19 Standard Biotools 3142001B 1.6 μL CCR6 144Nd G034E3 Standard Biotools 3141003A 1.88 μL CD20 147Sm 2H7 Standard Biotools 3147001B 0.7 μL ICOS 148Nd C398.4A Standard Biotools 3148019B 1 μL CCR4 149Sm L291H4 Standard Biotools 3149029A 1.5 μL CD40L 152Sm TRAP1 BD Biosciences 555698 3 μL TIGIT 153Eu MBSA43 Standard Biotools 3153019B 2 μL CD3 154Sm UCHT1 Standard Biotools 3154003B 0.5 μL CD27 155Gd L128 Standard Biotools 3155001B 1 μL CXCR3 156Gd G025H7 Standard Biotools 3156004B 0.8 μL CCR7 159 Tb G043H7 Standard Biotools 3159003A 1 μL CD30 162Dy BY88 BioLegend 333902 3 μL CXCR5 164Dy RF8B2 Standard Biotools 3164029B 1.2 μL CD45RO 165Ho UCHL1 Standard Biotools 3165011B 0.7 μL CD38 167Er HIT2 Standard Biotools 3167001B 0.6 μL CD45RA 170Er HI100 Standard Biotools 3171002B 1.6 μL HLA- DR 174Yb L243 Standard Biotools 3174001B 0.7 μL CD279/PD- 1 175Lu EH12.2H7 Standard Biotools 3175008B 1 μL CD127 176Yb A019D5 Standard Biotools 3176004B 0.7 μL CTLA4 194Pt Ipilimumab BMS ACB3065 2.5 μL CD57 198Pt NK- 1 BD Biosciences 555618 1 μL CD16 209Bi 3G8 Standard Biotools 3209002B 1.5 μL TABLE 2 | Antibodies used for the mass cytometry intracellular characterisation of tonsillar- derived cells.

    Techniques: Expressing, MANN-WHITNEY

    FIGURE 6 | Similar phenotypic composition of follicular and extrafollicular CD8 T cells in reactive lymph nodes. (A) Representative mIF images showing the expression of CD20 (red), CD8 (yellow) and GrzB (magenta) in an LN (scale bar: 500 μm). Inserts show the CD8, GrzB staining pattern in a zoomed area. (B) The histocytometry gating scheme for the identification of CD3hiCD4loCD8hi T cells in the EF and total F of an LN. (C) Heatmap showing the prevalence (judged by absolute cell counts) of FlowSOM identified CD8 T cell subsets (P0–P7) in EF and F area for each LN tissue in- vestigated (D) Dot plot graph showing the cell counts of the P1 and P5 subsets in EF (n = 4, open circles) and F (n = 4, grey circles) areas (right). Each circle represents a different LN donor (E) 2D histocytometry plot projecting the localisation of CD3hiCD4loCD8hi and CD3hiPD1hi TFH cells across follicular areas. Representative plots from one LN are shown. (F) Dot plot graphs showing accumulated data for the analysis of the minimum dis- tance (left panel) between follicular CD3hiCD4loCD8hi cells and CD3hiPD1hiCD57hi (open circles) or CD3hiPD1hiCD57lo (grey circles) TFH cell subsets and corresponding calculated cross-G function (right panel). Each dot represents a follicle. Statistical analysis was performed using the Wilcoxon test, and p values are listed. (G) Follicular areas from four LNs were analysed, with each dot representing a follicle. The regression analysis between concatenated follicular CD3hiCD4hiCD8loPD1hi TFH and follicular CD3hiCD4loCD8hi T cell counts, for all reactive lymph node follicles of one repre- sentative LN, is shown. The R and p values are listed.

    Journal: Immunology

    Article Title: Delineation of the Human Germinal Centre Immune Landscape Using Multiplex Imaging Analysis.

    doi: 10.1111/imm.13955

    Figure Lengend Snippet: FIGURE 6 | Similar phenotypic composition of follicular and extrafollicular CD8 T cells in reactive lymph nodes. (A) Representative mIF images showing the expression of CD20 (red), CD8 (yellow) and GrzB (magenta) in an LN (scale bar: 500 μm). Inserts show the CD8, GrzB staining pattern in a zoomed area. (B) The histocytometry gating scheme for the identification of CD3hiCD4loCD8hi T cells in the EF and total F of an LN. (C) Heatmap showing the prevalence (judged by absolute cell counts) of FlowSOM identified CD8 T cell subsets (P0–P7) in EF and F area for each LN tissue in- vestigated (D) Dot plot graph showing the cell counts of the P1 and P5 subsets in EF (n = 4, open circles) and F (n = 4, grey circles) areas (right). Each circle represents a different LN donor (E) 2D histocytometry plot projecting the localisation of CD3hiCD4loCD8hi and CD3hiPD1hi TFH cells across follicular areas. Representative plots from one LN are shown. (F) Dot plot graphs showing accumulated data for the analysis of the minimum dis- tance (left panel) between follicular CD3hiCD4loCD8hi cells and CD3hiPD1hiCD57hi (open circles) or CD3hiPD1hiCD57lo (grey circles) TFH cell subsets and corresponding calculated cross-G function (right panel). Each dot represents a follicle. Statistical analysis was performed using the Wilcoxon test, and p values are listed. (G) Follicular areas from four LNs were analysed, with each dot representing a follicle. The regression analysis between concatenated follicular CD3hiCD4hiCD8loPD1hi TFH and follicular CD3hiCD4loCD8hi T cell counts, for all reactive lymph node follicles of one repre- sentative LN, is shown. The R and p values are listed.

    Article Snippet: Amount Rhodium 103Rh Cell- ID Standard Biotools 201103A 0.6 μL CD8 113ln RPA- T8 BioLegend 301018 0.6 μL CD4 115In RPA- T4 BioLegend 300515 0.6 μL CCR6 141Pr 11A9 Standard Biotools 3141014A 1 μL CD19 142Nd HIB19 Standard Biotools 3142001B 1.6 μL CCR6 144Nd G034E3 Standard Biotools 3141003A 1.88 μL CD20 147Sm 2H7 Standard Biotools 3147001B 0.7 μL ICOS 148Nd C398.4A Standard Biotools 3148019B 1 μL CCR4 149Sm L291H4 Standard Biotools 3149029A 1.5 μL CD40L 152Sm TRAP1 BD Biosciences 555698 3 μL TIGIT 153Eu MBSA43 Standard Biotools 3153019B 2 μL CD3 154Sm UCHT1 Standard Biotools 3154003B 0.5 μL CD27 155Gd L128 Standard Biotools 3155001B 1 μL CXCR3 156Gd G025H7 Standard Biotools 3156004B 0.8 μL CCR7 159 Tb G043H7 Standard Biotools 3159003A 1 μL CD30 162Dy BY88 BioLegend 333902 3 μL CXCR5 164Dy RF8B2 Standard Biotools 3164029B 1.2 μL CD45RO 165Ho UCHL1 Standard Biotools 3165011B 0.7 μL CD38 167Er HIT2 Standard Biotools 3167001B 0.6 μL CD45RA 170Er HI100 Standard Biotools 3171002B 1.6 μL HLA- DR 174Yb L243 Standard Biotools 3174001B 0.7 μL CD279/PD- 1 175Lu EH12.2H7 Standard Biotools 3175008B 1 μL CD127 176Yb A019D5 Standard Biotools 3176004B 0.7 μL CTLA4 194Pt Ipilimumab BMS ACB3065 2.5 μL CD57 198Pt NK- 1 BD Biosciences 555618 1 μL CD16 209Bi 3G8 Standard Biotools 3209002B 1.5 μL TABLE 2 | Antibodies used for the mass cytometry intracellular characterisation of tonsillar- derived cells.

    Techniques: Expressing, Staining

    FIGURE 7 | No significant differences between tonsillar and LN tissues with respect to innate immune cell subset prevalence. (A) Frequency of immune subsets from live gated cells. Colour code represents an individual (n = 3). (B) Representative mIF images showing the expression of FDC (green), IL21 (cyan), CXCL13 (grey), CD11c (yellow), CD68 (red) and CD163 (magenta) in one tonsil (scale bar: 300 μm). Inserts show the expression of individual biomarkers in a zoomed area. (C) The histocytometry gating scheme for the identification of F, EF areas and relevant cell subsets in a tonsil is shown. Dot plots showing the normalised cell counts of follicular CD4hiIL10hi, CD4hiCXCL13hi and CD4hiIL21hi T cells in LNs (n = 4, open circles) and tonsillar (n = 4, closed circles) follicular areas. Statistical analysis was performed using the Mann–Whitney U-test. (D) Representative mIF images showing the expression of FOXP3 (green), CD25 (magenta), PD1 (yellow) and CD20 (blue) in one LNs. (E) 2D Histocytometry plots show- ing the gating scheme for the identification of follicular CD4hiCD25loFOXP3hi and CD4hiCD25hiFOXP3hi cells as well as the co-expression of FOXP3 and PD1 (left panel). The relative positioning of FOXP3hiCD25loCD4hi of CD4hiCD25hiFOXP3hi T cells across the follicular areas is shown in the right panel. (F) Dot plot showing the absolute counts of CD4hiCD25loFOXP3hi and CD4hiCD25hiFOXP3hi T cells in individual follicles from three LNs an- alysed. Data were analysed using the Wilcoxon test. (G) The regression analyses between TFH and CD4hiCD25loFOXP3hi or CD4hiCD25hiFOXP3hi T cells in individual follicles from three LNs analysed are shown. Each dot represents a follicle. The R and p values are also listed.

    Journal: Immunology

    Article Title: Delineation of the Human Germinal Centre Immune Landscape Using Multiplex Imaging Analysis.

    doi: 10.1111/imm.13955

    Figure Lengend Snippet: FIGURE 7 | No significant differences between tonsillar and LN tissues with respect to innate immune cell subset prevalence. (A) Frequency of immune subsets from live gated cells. Colour code represents an individual (n = 3). (B) Representative mIF images showing the expression of FDC (green), IL21 (cyan), CXCL13 (grey), CD11c (yellow), CD68 (red) and CD163 (magenta) in one tonsil (scale bar: 300 μm). Inserts show the expression of individual biomarkers in a zoomed area. (C) The histocytometry gating scheme for the identification of F, EF areas and relevant cell subsets in a tonsil is shown. Dot plots showing the normalised cell counts of follicular CD4hiIL10hi, CD4hiCXCL13hi and CD4hiIL21hi T cells in LNs (n = 4, open circles) and tonsillar (n = 4, closed circles) follicular areas. Statistical analysis was performed using the Mann–Whitney U-test. (D) Representative mIF images showing the expression of FOXP3 (green), CD25 (magenta), PD1 (yellow) and CD20 (blue) in one LNs. (E) 2D Histocytometry plots show- ing the gating scheme for the identification of follicular CD4hiCD25loFOXP3hi and CD4hiCD25hiFOXP3hi cells as well as the co-expression of FOXP3 and PD1 (left panel). The relative positioning of FOXP3hiCD25loCD4hi of CD4hiCD25hiFOXP3hi T cells across the follicular areas is shown in the right panel. (F) Dot plot showing the absolute counts of CD4hiCD25loFOXP3hi and CD4hiCD25hiFOXP3hi T cells in individual follicles from three LNs an- alysed. Data were analysed using the Wilcoxon test. (G) The regression analyses between TFH and CD4hiCD25loFOXP3hi or CD4hiCD25hiFOXP3hi T cells in individual follicles from three LNs analysed are shown. Each dot represents a follicle. The R and p values are also listed.

    Article Snippet: Amount Rhodium 103Rh Cell- ID Standard Biotools 201103A 0.6 μL CD8 113ln RPA- T8 BioLegend 301018 0.6 μL CD4 115In RPA- T4 BioLegend 300515 0.6 μL CCR6 141Pr 11A9 Standard Biotools 3141014A 1 μL CD19 142Nd HIB19 Standard Biotools 3142001B 1.6 μL CCR6 144Nd G034E3 Standard Biotools 3141003A 1.88 μL CD20 147Sm 2H7 Standard Biotools 3147001B 0.7 μL ICOS 148Nd C398.4A Standard Biotools 3148019B 1 μL CCR4 149Sm L291H4 Standard Biotools 3149029A 1.5 μL CD40L 152Sm TRAP1 BD Biosciences 555698 3 μL TIGIT 153Eu MBSA43 Standard Biotools 3153019B 2 μL CD3 154Sm UCHT1 Standard Biotools 3154003B 0.5 μL CD27 155Gd L128 Standard Biotools 3155001B 1 μL CXCR3 156Gd G025H7 Standard Biotools 3156004B 0.8 μL CCR7 159 Tb G043H7 Standard Biotools 3159003A 1 μL CD30 162Dy BY88 BioLegend 333902 3 μL CXCR5 164Dy RF8B2 Standard Biotools 3164029B 1.2 μL CD45RO 165Ho UCHL1 Standard Biotools 3165011B 0.7 μL CD38 167Er HIT2 Standard Biotools 3167001B 0.6 μL CD45RA 170Er HI100 Standard Biotools 3171002B 1.6 μL HLA- DR 174Yb L243 Standard Biotools 3174001B 0.7 μL CD279/PD- 1 175Lu EH12.2H7 Standard Biotools 3175008B 1 μL CD127 176Yb A019D5 Standard Biotools 3176004B 0.7 μL CTLA4 194Pt Ipilimumab BMS ACB3065 2.5 μL CD57 198Pt NK- 1 BD Biosciences 555618 1 μL CD16 209Bi 3G8 Standard Biotools 3209002B 1.5 μL TABLE 2 | Antibodies used for the mass cytometry intracellular characterisation of tonsillar- derived cells.

    Techniques: Expressing, MANN-WHITNEY